Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17% with usual care and 24% had time-in-range (TIR) above 70% […]
Category Archives: Pr Newswire
TAIPEI, June 22, 2024 /PRNewswire/ — The prestigious 2024 Tang Prize Laureates have been announced, recognizing outstanding contributions in various fields. The Tang Prize in Sustainable Development is awarded to American chemist Omar M. Yaghi. In the field of Biopharmaceutical Science, the prize is jointly awarded to Joel F. Habener, Svetlana Mojsov, and Jens Juul Holst. […]
MUNICH, June 22, 2024 /PRNewswire/ — On June 19, CATL unveiled TENER, the world’s first mass-producible energy storage system with zero degradation in the first five years of use. CATL unveiled this breakthrough technology at ees Europe, the largest and most international exhibition for batteries and energy storage systems in Europe. CATL booth ees Europe Powering […]
VANCOUVER, BC, June 22, 2024 /PRNewswire/ — Wondershare has announced the latest update to its industry-leading video editing software, Filmora 13.5. This version introduces upgraded features designed to augment editors’ creativity and improve efficiency while delivering high-quality professional content. Wondershare Filmora 13.5 Unveils Upgraded AI Toolkit for Creators Filmora 13.5 enhances its text capabilities by […]
Pr Newswire
Teladoc Health is Providing Free Virtual Health Care Services to New Mexico Residents Impacted by Wildfires
22
Jun
Jun
PURCHASE, NY, June 21, 2024 (GLOBE NEWSWIRE) — Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, is providing free, 24/7 general medical telehealth visits to New Mexico residents, first responders and others directly impacted by the devastating wildfires. Individuals in New Mexico who have been displaced or who cannot access medical care […]
Pr Newswire
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
22
Jun
Jun
TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting in greater weight loss, increased fat mass loss and relative preservation of lean mass FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of […]
Pr Newswire
Goodness Growth Holdings Announces Voting Results of Annual General and Special Meeting of Shareholders
22
Jun
Jun
MINNEAPOLIS, June 21, 2024 (GLOBE NEWSWIRE) — Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today announced the voting results of its Annual General and Special Meeting of shareholders, which was held on Friday, […]
22
Jun
Jun
SAN CARLOS, Calif., June 21, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 20, 2024 (the “Date of Grant”), the Company approved the grant of […]
Pr Newswire
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
22
Jun
Jun
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in more than 30 years for patients with CIDP Third approved indication for VYVGART® and VYVGART Hytrulo franchise Management to host conference call on June 21, 2024 at 11:00pm CET […]
A Phase 1 study of oral ecnoglutide (1871-LB) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 weeks of dosing). Improved oral bioavailability enables a 15 to 30 mg daily dose of oral ecnoglutide to match or exceed the plasma exposure of weekly subcutaneous GLP-1 analogs […]